Entasis Therapeutics Holdings Inc. ETTX announced that it has signed a definitive merger agreement with Innoviva, Inc. INVA, wherein the latter will acquire all the outstanding shares it does not own ...

Entasis Therapeutics steered its lead antibiotic candidate through late-stage clinical development with help from Innoviva, which has steadily invested in the company over the past two years and now ...

Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share ...

WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...

WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...

Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections ...

WASHINGTON — Entasis Therapeutics announced at the World Anti-Microbial Resistance Congress that it has enrolled the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of ...

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...

Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...

WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, reported positive topline ...

Entasis Therapeutics has progress to report in its quest to bring patients an antibiotic that can take on drug-resistant bacteria. The company’s lead antibiotic candidate has met the main goal of a ...